Thomas Pillow

Dr. Thomas Pillow


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2019 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
TPThomas Pillow
Thomas Pillow
PAPragya Adhikari
Pragya Adhikari
RBRobert A. Blake
Robert A. Blake
JCJinhua Chen
Jinhua Chen
GRGeoffrey Del Rosario
Geoffrey Del Rosario
PDPeter S. Dragovich
Peter S. Dragovich

22 August 2016 in Chemical Science
Verified
Journal Article
Open access
PDF file
TPThomas Pillow
Thomas Pillow
JSJack D. Sadowsky
Jack D. Sadowsky
DZDonglu Zhang
Donglu Zhang
SYShang-Fan Yu
Shang-Fan Yu
GRGeoffrey Del Rosario
Geoffrey Del Rosario
JFJohn A. Flygare
John A. Flygare
A novel bioconjugation strategy utilizes a disulfide bond to site-specifically couple a small molecule drug to an antibody, enabling both high circulation stability and quick intracellular release.

21 December 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
BWBinQing Wei
BinQing Wei
JGJanet Gunzner-Toste
Janet Gunzner-Toste
HYHui Yao
Hui Yao
TWTao Wang
Tao Wang
JWJing Wang
Jing Wang
BSBrian Safina
Brian Safina

18 September 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TPThomas Pillow
Thomas Pillow
JTJanet Tien
Janet Tien
KPKathryn L. Parsons-Reponte
Kathryn L. Parsons-Reponte
SBSunil Bhakta
Sunil Bhakta
HLHao Li
Hao Li
JJJagath Reddy Junutula
Jagath Reddy Junutula

21 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DHDavid S. Hewings
David S. Hewings
JHJohanna Heideker
Johanna Heideker
TMTaylur P. Ma
Taylur P. Ma
AAAndrew P. AhYoung
Andrew P. AhYoung
FOFarid El Oualid
Farid El Oualid
IWIngrid E. Wertz
Ingrid E. Wertz
Activity-based probes (ABPs) are widely used to monitor the activity of enzyme families in biological systems. Inferring enzyme activity from probe reactivity requires that the probe reacts with the enzyme at its active site; however, probe-labeling sites are rarely verified. Here we present an enhanced chemoproteomic approach to evaluate the activity and probe reactivity of deubiquitinase enzymes, using bioorthogonally tagged ABPs and a sequential on-bead digestion protocol to enhance the identification of probe-labeling sites. We confirm probe labeling of deubiquitinase catalytic Cys residues and reveal unexpected labeling of deubiquitinases on non-catalytic Cys residues and of non-deubiquitinase proteins. In doing so, we identify ZUFSP (ZUP1) as a previously unannotated deubiquitinase with high selectivity toward cleaving K63-linked chains. ZUFSP interacts with and modulates ubiquitination of the replication protein A (RPA) complex. Our reactive-site-centric chemoproteomics method is broadly applicable for identifying the reaction sites of covalent molecules, which may expand our understanding of enzymatic mechanisms.

1 May 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TPThomas Pillow
Thomas Pillow
MSMelissa Schutten
Melissa Schutten
SYShang-Fan Yu
Shang-Fan Yu
RORachana Ohri
Rachana Ohri
JSJack Sadowsky
Jack Sadowsky
JJJagath Reddy Junutula
Jagath Reddy Junutula
A novel disulfide linker was designed to enable a direct connection between cytotoxic pyrrolobenzodiazepine (PBD) drugs and the cysteine on a targeting antibody for use in antibody–drug conjugates (ADCs). ADCs composed of a cysteine-engineered antibody were armed with a PBD using a self-immolative disulfide linker. Both the chemical linker and the antibody site were optimized for this new bioconjugation strategy to provide a highly stable and efficacious ADC. This novel disulfide ADC was compared with a conjugate containing the same PBD drug, but attached to the antibody via a peptide linker. Both ADCs had similar efficacy in mice bearing human tumor xenografts. Safety studies in rats revealed that the disulfide-linked ADC had a higher MTD than the peptide-linked ADC. Overall, these data suggest that the novel self-immolative disulfide linker represents a valuable way to construct ADCs with equivalent efficacy and improved safety. Mol Cancer Ther; 16(5); 871–8. ©2017 AACR.